All panel figures (Figure S2) indicated an increase in the likelihood of the alternative hypothesis predicting a reduced excellent response, NED in final follow-up, tumor size ≤10 mm, and classic cancer subtype in patients with higher CHK2 expression, lower absence of vascular invasion, and age <55 years in patients with TP53 gene deletion and positive p53 together with TP53 gene deletion. The gene discussed is CHEK2; the disease is cancer.